Patrick G. Lepore - Mar 20, 2023 Form 4 Insider Report for VYNE Therapeutics Inc. (VYNE)

Role: Director
Signature: /s/ Mutya Harsch, as attorney-in-fact for Patrick G. LePore
Stock symbol: VYNE
Transactions as of: Mar 20, 2023
Transactions value $: $49,680
Form type: 4
Date filed: 3/22/2023, 04:03 PM
Previous filing: Nov 14, 2022
Next filing: Nov 17, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VYNE	Common Stock	Purchase	$49.7K	+20K	+576.04%	$2.48	23.5K	Mar 20, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $2.464 to $2.5199, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2	On February 10, 2023, the Issuer effected a one-for-18 reverse split of its Common Stock. The number of securities reported reflects the reverse split.

Content

The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $2.464 to $2.5199, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

On February 10, 2023, the Issuer effected a one-for-18 reverse split of its Common Stock. The number of securities reported reflects the reverse split.